ACE inhibitors and angiotensin receptor blockers (ARBs) confer different cardiovascular benefits in hemodialysis (HD) patients, researchers found.

In a crossover study, 15 HD patients received placebo, the ACE inhibitor ramipril 5 mg per day for seven days, and the ARB valsartan 160 mg/day for another seven days, with a washout period of three weeks between treatments. Neither ramipril nor valsartan affected blood pressure during dialysis treatment.

Valsartan induced a greater anti-inflammatory effect compared with ramipril, but ramipril appeared to prevent dialysis-induced endothelial dysfunction, T. Alp Ikizler, MD, and colleagues reported online in the Journal of the American Society of Nephrology.

Continue Reading